APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rare Disease Pharmaceutical Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rare Disease Pharmaceutical Service Market Analysis and Forecast 2026-2032

2 May 2026243 pages

Choose your research edition.

Industry ResearchRare Disease Pharmaceutical Service Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Disease Pharmaceutical Service Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Rare Disease Pharmaceutical Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Disease Pharmaceutical Service Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Disease Pharmaceutical Service Market Analysis and Forecast 2026-2032243 pages · $4,950 USD

Market perspective

The global Rare Disease Pharmaceutical Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Rare Disease Pharmaceutical Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rare Disease Pharmaceutical Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rare Disease Pharmaceutical Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rare Disease Pharmaceutical Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Rare Disease Pharmaceutical Service include Ultragenyx, Chiesi, Sciensus, Abbvie, Orpharma, Amgen, Recordati, Novartis and Celgene, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Rare Disease Pharmaceutical Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rare Disease Pharmaceutical Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Rare Disease Pharmaceutical Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rare Disease Pharmaceutical Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rare Disease Pharmaceutical Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rare Disease Pharmaceutical Service revenue, projected growth trends, production technology, application and end-user industry.

Rare Disease Pharmaceutical Service Segment by Company

Ultragenyx

Chiesi

Sciensus

Abbvie

Orpharma

Amgen

Recordati

Novartis

Celgene

Amryt Pharma

Johnson & Johnson

GSK

Shire

Merck

Pfizer

Biogen

Sanofi

AstraZeneca

Takeda

Rare Disease Pharmaceutical Service Segment by Type

Drug Discovery

Clinical Trials

Others

Rare Disease Pharmaceutical Service Segment by Application

Congenital and Genetic Diseases

Tumors and Cancer

Endocrine Diseases

Others

Rare Disease Pharmaceutical Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Pharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Pharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Pharmaceutical Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Rare Disease Pharmaceutical Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Rare Disease Pharmaceutical Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Disease Pharmaceutical Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Drug Discovery Major Player Table 3. Clinical Trials Major Player Table 4. Others Major Player Table 5. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Congenital and Genetic Diseases Major Player Table 7. Tumors and Cancer Major Player Table 8. Endocrine Diseases Major Player Table 9. Others Major Player Table 10. Rare Disease Pharmaceutical Service Industry Trends Table 11. Rare Disease Pharmaceutical Service Industry Drivers Table 12. Rare Disease Pharmaceutical Service Industry Opportunities and Challenges Table 13. Rare Disease Pharmaceutical Service Industry Restraints Table 14. Global Rare Disease Pharmaceutical Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Rare Disease Pharmaceutical Service Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Rare Disease Pharmaceutical Service Market Share by Region (2021-2026) Table 17. Global Rare Disease Pharmaceutical Service Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Rare Disease Pharmaceutical Service Market Share by Region (2027-2032) Table 19. Global Rare Disease Pharmaceutical Service Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Rare Disease Pharmaceutical Service Revenue Market Share by Players (2021-2026) Table 21. Global Rare Disease Pharmaceutical Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Rare Disease Pharmaceutical Service Key Players Headquarters & Area Served Table 23. Global Rare Disease Pharmaceutical Service Players, Product Type & Application Table 24. Global Rare Disease Pharmaceutical Service Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Rare Disease Pharmaceutical Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Rare Disease Pharmaceutical Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Rare Disease Pharmaceutical Service Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Rare Disease Pharmaceutical Service Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2021-2026) Table 31. Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2027-2032) Table 32. Global Rare Disease Pharmaceutical Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Rare Disease Pharmaceutical Service Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Rare Disease Pharmaceutical Service Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2021-2026) Table 36. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2027-2032) Table 37. Ultragenyx Company Information Table 38. Ultragenyx Business Overview Table 39. Ultragenyx Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio Table 41. Ultragenyx Recent Development Table 42. Chiesi Company Information Table 43. Chiesi Business Overview Table 44. Chiesi Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Chiesi Rare Disease Pharmaceutical Service Product Portfolio Table 46. Chiesi Recent Development Table 47. Sciensus Company Information Table 48. Sciensus Business Overview Table 49. Sciensus Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sciensus Rare Disease Pharmaceutical Service Product Portfolio Table 51. Sciensus Recent Development Table 52. Abbvie Company Information Table 53. Abbvie Business Overview Table 54. Abbvie Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Abbvie Rare Disease Pharmaceutical Service Product Portfolio Table 56. Abbvie Recent Development Table 57. Orpharma Company Information Table 58. Orpharma Business Overview Table 59. Orpharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Orpharma Rare Disease Pharmaceutical Service Product Portfolio Table 61. Orpharma Recent Development Table 62. Amgen Company Information Table 63. Amgen Business Overview Table 64. Amgen Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Amgen Rare Disease Pharmaceutical Service Product Portfolio Table 66. Amgen Recent Development Table 67. Recordati Company Information Table 68. Recordati Business Overview Table 69. Recordati Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Recordati Rare Disease Pharmaceutical Service Product Portfolio Table 71. Recordati Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Novartis Rare Disease Pharmaceutical Service Product Portfolio Table 76. Novartis Recent Development Table 77. Celgene Company Information Table 78. Celgene Business Overview Table 79. Celgene Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Celgene Rare Disease Pharmaceutical Service Product Portfolio Table 81. Celgene Recent Development Table 82. Amryt Pharma Company Information Table 83. Amryt Pharma Business Overview Table 84. Amryt Pharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio Table 86. Amryt Pharma Recent Development Table 87. Johnson & Johnson Company Information Table 88. Johnson & Johnson Business Overview Table 89. Johnson & Johnson Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio Table 91. Johnson & Johnson Recent Development Table 92. GSK Company Information Table 93. GSK Business Overview Table 94. GSK Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. GSK Rare Disease Pharmaceutical Service Product Portfolio Table 96. GSK Recent Development Table 97. Shire Company Information Table 98. Shire Business Overview Table 99. Shire Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Shire Rare Disease Pharmaceutical Service Product Portfolio Table 101. Shire Recent Development Table 102. Merck Company Information Table 103. Merck Business Overview Table 104. Merck Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Merck Rare Disease Pharmaceutical Service Product Portfolio Table 106. Merck Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Pfizer Rare Disease Pharmaceutical Service Product Portfolio Table 111. Pfizer Recent Development Table 112. Biogen Company Information Table 113. Biogen Business Overview Table 114. Biogen Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Biogen Rare Disease Pharmaceutical Service Product Portfolio Table 116. Biogen Recent Development Table 117. Sanofi Company Information Table 118. Sanofi Business Overview Table 119. Sanofi Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Sanofi Rare Disease Pharmaceutical Service Product Portfolio Table 121. Sanofi Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio Table 126. AstraZeneca Recent Development Table 127. Takeda Company Information Table 128. Takeda Business Overview Table 129. Takeda Rare Disease Pharmaceutical Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Takeda Rare Disease Pharmaceutical Service Product Portfolio Table 131. Takeda Recent Development Table 132. North America Rare Disease Pharmaceutical Service Revenue by Type (2021-2026) & (US$ Million) Table 133. North America Rare Disease Pharmaceutical Service Revenue by Type (2027-2032) & (US$ Million) Table 134. North America Rare Disease Pharmaceutical Service Revenue by Application (2021-2026) & (US$ Million) Table 135. North America Rare Disease Pharmaceutical Service Revenue by Application (2027-2032) & (US$ Million) Table 136. North America Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Rare Disease Pharmaceutical Service Revenue by Country (2021-2026) & (US$ Million) Table 138. North America Rare Disease Pharmaceutical Service Revenue by Country (US$ Million) & (2027-2032) Table 139. Europe Rare Disease Pharmaceutical Service Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe Rare Disease Pharmaceutical Service Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe Rare Disease Pharmaceutical Service Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe Rare Disease Pharmaceutical Service Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Rare Disease Pharmaceutical Service Revenue by Country (2021-2026) & (US$ Million) Table 145. Europe Rare Disease Pharmaceutical Service Revenue by Country (US$ Million) & (2027-2032) Table 146. China Rare Disease Pharmaceutical Service Revenue by Type (2021-2026) & (US$ Million) Table 147. China Rare Disease Pharmaceutical Service Revenue by Type (2027-2032) & (US$ Million) Table 148. China Rare Disease Pharmaceutical Service Revenue by Application (2021-2026) & (US$ Million) Table 149. China Rare Disease Pharmaceutical Service Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Rare Disease Pharmaceutical Service Revenue by Type (2021-2026) & (US$ Million) Table 151. Asia Rare Disease Pharmaceutical Service Revenue by Type (2027-2032) & (US$ Million) Table 152. Asia Rare Disease Pharmaceutical Service Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia Rare Disease Pharmaceutical Service Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Rare Disease Pharmaceutical Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Asia Rare Disease Pharmaceutical Service Revenue by Region (US$ Million) & (2021-2026) Table 156. Asia Rare Disease Pharmaceutical Service Revenue by Region (US$ Million) & (2027-2032) Table 157. SAMEA Rare Disease Pharmaceutical Service Revenue by Type (2021-2026) & (US$ Million) Table 158. SAMEA Rare Disease Pharmaceutical Service Revenue by Type (2027-2032) & (US$ Million) Table 159. SAMEA Rare Disease Pharmaceutical Service Revenue by Application (2021-2026) & (US$ Million) Table 160. SAMEA Rare Disease Pharmaceutical Service Revenue by Application (2027-2032) & (US$ Million) Table 161. SAMEA Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. SAMEA Rare Disease Pharmaceutical Service Revenue by Country (2021-2026) & (US$ Million) Table 163. SAMEA Rare Disease Pharmaceutical Service Revenue by Country (US$ Million) & (2027-2032) Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Rare Disease Pharmaceutical Service Image Figure 2. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rare Disease Pharmaceutical Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Drug Discovery Image Figure 5. Clinical Trials Image Figure 6. Others Image Figure 7. Global Rare Disease Pharmaceutical Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Rare Disease Pharmaceutical Service Market Size Share 2021 VS 2025 VS 2032 Figure 9. Congenital and Genetic Diseases Image Figure 10. Tumors and Cancer Image Figure 11. Endocrine Diseases Image Figure 12. Others Image Figure 13. Global Rare Disease Pharmaceutical Service Market Size (US$ Million) & (2021-2032) Figure 14. Global Rare Disease Pharmaceutical Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Rare Disease Pharmaceutical Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Rare Disease Pharmaceutical Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Rare Disease Pharmaceutical Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Rare Disease Pharmaceutical Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2021-2032) Figure 21. Global Rare Disease Pharmaceutical Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2021-2032) Figure 24. North America Rare Disease Pharmaceutical Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032) Figure 26. North America Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032) Figure 27. North America Rare Disease Pharmaceutical Service Revenue Share by Country (2021-2032) Figure 28. United States Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Rare Disease Pharmaceutical Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032) Figure 33. Europe Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032) Figure 34. Europe Rare Disease Pharmaceutical Service Revenue Share by Country (2021-2032) Figure 35. Germany Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Rare Disease Pharmaceutical Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032) Figure 45. China Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032) Figure 46. Asia Rare Disease Pharmaceutical Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032) Figure 48. Asia Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032) Figure 49. Asia Rare Disease Pharmaceutical Service Revenue Share by Region (2021-2032) Figure 50. Japan Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Rare Disease Pharmaceutical Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032) Figure 58. SAMEA Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032) Figure 59. SAMEA Rare Disease Pharmaceutical Service Revenue Share by Country (2021-2032) Figure 60. Brazil Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Rare Disease Pharmaceutical Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Drug Discovery
  • Clinical Trials
  • Others
Applications
  • Congenital and Genetic Diseases
  • Tumors and Cancer
  • Endocrine Diseases
  • Others
Companies covered
  • Ultragenyx
  • Chiesi
  • Sciensus
  • Abbvie
  • Orpharma
  • Amgen
  • Recordati
  • Novartis
  • Celgene
  • Amryt Pharma
  • Johnson & Johnson
  • GSK
  • Shire
  • Merck
  • Pfizer
  • Biogen
  • Sanofi
  • AstraZeneca
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rare Disease Pharmaceutical Service Market by Type
  3. 1.2.1 Global Rare Disease Pharmaceutical Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Drug Discovery
  5. 1.2.3 Clinical Trials
  6. 1.2.4 Others
  7. 1.3 Rare Disease Pharmaceutical Service Market by Application
  8. 1.3.1 Global Rare Disease Pharmaceutical Service Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Congenital and Genetic Diseases
  10. 1.3.3 Tumors and Cancer
  11. 1.3.4 Endocrine Diseases
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Rare Disease Pharmaceutical Service Market Dynamics
  1. 2.1 Rare Disease Pharmaceutical Service Industry Trends
  2. 2.2 Rare Disease Pharmaceutical Service Industry Drivers
  3. 2.3 Rare Disease Pharmaceutical Service Industry Opportunities and Challenges
  4. 2.4 Rare Disease Pharmaceutical Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Rare Disease Pharmaceutical Service Market Perspective (2021-2032)
  2. 3.2 Global Rare Disease Pharmaceutical Service Growth Trends by Region
  3. 3.2.1 Global Rare Disease Pharmaceutical Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rare Disease Pharmaceutical Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Rare Disease Pharmaceutical Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Rare Disease Pharmaceutical Service Revenue by Players
  2. 4.1.1 Global Rare Disease Pharmaceutical Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Rare Disease Pharmaceutical Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Rare Disease Pharmaceutical Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rare Disease Pharmaceutical Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Rare Disease Pharmaceutical Service Key Players Headquarters & Area Served
  7. 4.4 Global Rare Disease Pharmaceutical Service Players, Product Type & Application
  8. 4.5 Global Rare Disease Pharmaceutical Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Rare Disease Pharmaceutical Service Market CR5 and HHI
  11. 4.6.3 2025 Rare Disease Pharmaceutical Service Tier 1, Tier 2, and Tier 3
5 Rare Disease Pharmaceutical Service Market Size by Type
  1. 5.1 Global Rare Disease Pharmaceutical Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Rare Disease Pharmaceutical Service Revenue by Type (2021-2032)
  3. 5.3 Global Rare Disease Pharmaceutical Service Revenue Market Share by Type (2021-2032)
6 Rare Disease Pharmaceutical Service Market Size by Application
  1. 6.1 Global Rare Disease Pharmaceutical Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Rare Disease Pharmaceutical Service Revenue by Application (2021-2032)
  3. 6.3 Global Rare Disease Pharmaceutical Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Ultragenyx
  2. 7.1.1 Ultragenyx Company Information
  3. 7.1.2 Ultragenyx Business Overview
  4. 7.1.3 Ultragenyx Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
  6. 7.1.5 Ultragenyx Recent Developments
  7. 7.2 Chiesi
  8. 7.2.1 Chiesi Company Information
  9. 7.2.2 Chiesi Business Overview
  10. 7.2.3 Chiesi Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Chiesi Rare Disease Pharmaceutical Service Product Portfolio
  12. 7.2.5 Chiesi Recent Developments
  13. 7.3 Sciensus
  14. 7.3.1 Sciensus Company Information
  15. 7.3.2 Sciensus Business Overview
  16. 7.3.3 Sciensus Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sciensus Rare Disease Pharmaceutical Service Product Portfolio
  18. 7.3.5 Sciensus Recent Developments
  19. 7.4 Abbvie
  20. 7.4.1 Abbvie Company Information
  21. 7.4.2 Abbvie Business Overview
  22. 7.4.3 Abbvie Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Abbvie Rare Disease Pharmaceutical Service Product Portfolio
  24. 7.4.5 Abbvie Recent Developments
  25. 7.5 Orpharma
  26. 7.5.1 Orpharma Company Information
  27. 7.5.2 Orpharma Business Overview
  28. 7.5.3 Orpharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Orpharma Rare Disease Pharmaceutical Service Product Portfolio
  30. 7.5.5 Orpharma Recent Developments
  31. 7.6 Amgen
  32. 7.6.1 Amgen Company Information
  33. 7.6.2 Amgen Business Overview
  34. 7.6.3 Amgen Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Amgen Rare Disease Pharmaceutical Service Product Portfolio
  36. 7.6.5 Amgen Recent Developments
  37. 7.7 Recordati
  38. 7.7.1 Recordati Company Information
  39. 7.7.2 Recordati Business Overview
  40. 7.7.3 Recordati Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Recordati Rare Disease Pharmaceutical Service Product Portfolio
  42. 7.7.5 Recordati Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Rare Disease Pharmaceutical Service Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Celgene
  50. 7.9.1 Celgene Company Information
  51. 7.9.2 Celgene Business Overview
  52. 7.9.3 Celgene Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Celgene Rare Disease Pharmaceutical Service Product Portfolio
  54. 7.9.5 Celgene Recent Developments
  55. 7.10 Amryt Pharma
  56. 7.10.1 Amryt Pharma Company Information
  57. 7.10.2 Amryt Pharma Business Overview
  58. 7.10.3 Amryt Pharma Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
  60. 7.10.5 Amryt Pharma Recent Developments
  61. 7.11 Johnson & Johnson
  62. 7.11.1 Johnson & Johnson Company Information
  63. 7.11.2 Johnson & Johnson Business Overview
  64. 7.11.3 Johnson & Johnson Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
  66. 7.11.5 Johnson & Johnson Recent Developments
  67. 7.12 GSK
  68. 7.12.1 GSK Company Information
  69. 7.12.2 GSK Business Overview
  70. 7.12.3 GSK Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 GSK Rare Disease Pharmaceutical Service Product Portfolio
  72. 7.12.5 GSK Recent Developments
  73. 7.13 Shire
  74. 7.13.1 Shire Company Information
  75. 7.13.2 Shire Business Overview
  76. 7.13.3 Shire Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Shire Rare Disease Pharmaceutical Service Product Portfolio
  78. 7.13.5 Shire Recent Developments
  79. 7.14 Merck
  80. 7.14.1 Merck Company Information
  81. 7.14.2 Merck Business Overview
  82. 7.14.3 Merck Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Merck Rare Disease Pharmaceutical Service Product Portfolio
  84. 7.14.5 Merck Recent Developments
  85. 7.15 Pfizer
  86. 7.15.1 Pfizer Company Information
  87. 7.15.2 Pfizer Business Overview
  88. 7.15.3 Pfizer Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Pfizer Rare Disease Pharmaceutical Service Product Portfolio
  90. 7.15.5 Pfizer Recent Developments
  91. 7.16 Biogen
  92. 7.16.1 Biogen Company Information
  93. 7.16.2 Biogen Business Overview
  94. 7.16.3 Biogen Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Biogen Rare Disease Pharmaceutical Service Product Portfolio
  96. 7.16.5 Biogen Recent Developments
  97. 7.17 Sanofi
  98. 7.17.1 Sanofi Company Information
  99. 7.17.2 Sanofi Business Overview
  100. 7.17.3 Sanofi Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Rare Disease Pharmaceutical Service Product Portfolio
  102. 7.17.5 Sanofi Recent Developments
  103. 7.18 AstraZeneca
  104. 7.18.1 AstraZeneca Company Information
  105. 7.18.2 AstraZeneca Business Overview
  106. 7.18.3 AstraZeneca Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  107. 7.18.4 AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
  108. 7.18.5 AstraZeneca Recent Developments
  109. 7.19 Takeda
  110. 7.19.1 Takeda Company Information
  111. 7.19.2 Takeda Business Overview
  112. 7.19.3 Takeda Rare Disease Pharmaceutical Service Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Takeda Rare Disease Pharmaceutical Service Product Portfolio
  114. 7.19.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Rare Disease Pharmaceutical Service Revenue (2021-2032)
  2. 8.2 North America Rare Disease Pharmaceutical Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Rare Disease Pharmaceutical Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Rare Disease Pharmaceutical Service Revenue by Type (2027-2032)
  5. 8.3 North America Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Rare Disease Pharmaceutical Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Rare Disease Pharmaceutical Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Rare Disease Pharmaceutical Service Revenue by Application (2027-2032)
  9. 8.5 North America Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Rare Disease Pharmaceutical Service Revenue by Country
  11. 8.6.1 North America Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Rare Disease Pharmaceutical Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Rare Disease Pharmaceutical Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Rare Disease Pharmaceutical Service Revenue (2021-2032)
  2. 9.2 Europe Rare Disease Pharmaceutical Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Rare Disease Pharmaceutical Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Rare Disease Pharmaceutical Service Revenue by Type (2027-2032)
  5. 9.3 Europe Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Rare Disease Pharmaceutical Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Rare Disease Pharmaceutical Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Rare Disease Pharmaceutical Service Revenue by Application (2027-2032)
  9. 9.5 Europe Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Rare Disease Pharmaceutical Service Revenue by Country
  11. 9.6.1 Europe Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Rare Disease Pharmaceutical Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Rare Disease Pharmaceutical Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Rare Disease Pharmaceutical Service Revenue (2021-2032)
  2. 10.2 China Rare Disease Pharmaceutical Service Revenue by Type (2021-2032)
  3. 10.2.1 China Rare Disease Pharmaceutical Service Revenue by Type (2021-2026)
  4. 10.2.2 China Rare Disease Pharmaceutical Service Revenue by Type (2027-2032)
  5. 10.3 China Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032)
  6. 10.4 China Rare Disease Pharmaceutical Service Revenue by Application (2021-2032)
  7. 10.4.1 China Rare Disease Pharmaceutical Service Revenue by Application (2021-2026)
  8. 10.4.2 China Rare Disease Pharmaceutical Service Revenue by Application (2027-2032)
  9. 10.5 China Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rare Disease Pharmaceutical Service Revenue (2021-2032)
  2. 11.2 Asia Rare Disease Pharmaceutical Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Rare Disease Pharmaceutical Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Rare Disease Pharmaceutical Service Revenue by Type (2027-2032)
  5. 11.3 Asia Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Rare Disease Pharmaceutical Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Rare Disease Pharmaceutical Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Rare Disease Pharmaceutical Service Revenue by Application (2027-2032)
  9. 11.5 Asia Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Rare Disease Pharmaceutical Service Revenue by Country
  11. 11.6.1 Asia Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Rare Disease Pharmaceutical Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Rare Disease Pharmaceutical Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rare Disease Pharmaceutical Service Revenue (2021-2032)
  2. 12.2 SAMEA Rare Disease Pharmaceutical Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Rare Disease Pharmaceutical Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Rare Disease Pharmaceutical Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Rare Disease Pharmaceutical Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Rare Disease Pharmaceutical Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Rare Disease Pharmaceutical Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Rare Disease Pharmaceutical Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Rare Disease Pharmaceutical Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Rare Disease Pharmaceutical Service Revenue by Country
  11. 12.6.1 SAMEA Rare Disease Pharmaceutical Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Rare Disease Pharmaceutical Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Rare Disease Pharmaceutical Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst